Qin W, Li Y, Liu B, et al. - In view of the wide use of intrathecal morphine infusion therapy via a percutaneous port (IMITPP) due to its relatively low initial cost, researchers here examined efficacy, complications, and the interval required to achieve the cost equivalence of IMITPP in patients with refractory cancer pain in China. In this retrospective chart review, they assessed cancer patients who were administered IMITPP at their hospital between April 2017 and April 2019. Outcomes suggest that with no serious complications, effective cancer pain management could be achieved with IMITPP. IMITPP would be economically beneficial for patients with higher doses of systemic opioids in a shorter time.